乙酰丙酮酸甲酯 | 20577-61-1

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 中文名称: 乙酰丙酮酸甲酯
• 中文别名: 乙酰丙酮甲酯；2,4-二氧代戊酸甲酯
• 英文名称: methyl 2,4-dioxopentanoate
• CAS: 20577-61-1
• 化学式: C₆H₈O₄
• mdl: MFCD00043638
• 分子量: 144.127
• InChiKey: OMHOEQINEXASKE-UHFFFAOYSA-N

物化性质

• 熔点：
  60-65 °C
• 沸点：
  195℃
• 密度：
  1.150
• 闪点：
  76℃
• 稳定性/保质期：
  如果遵照规格使用和储存，则不会分解。避免接触氧化物、还原剂、酸或碱。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  F,Xi
• 安全说明：
  S24/25,S26
• 危险类别码：
  R36
• WGK Germany：
  3
• 海关编码：
  2918300090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319
• 储存条件：
  将贮藏器密封，并将其存放在阴凉、干燥的地方，放入一个紧闭的容器中。

SDS

Name:	Methyl acetopyruvate Material Safety Data Sheet
Synonym:	None Known
CAS:	20577-61-1

Section 1 - Chemical Product MSDS Name:Methyl acetopyruvate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
20577-61-1	Methyl acetopyruvate	99%	243-891-3

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 20577-61-1: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Needles
Color: white - faint yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 62-63 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H8O4
Molecular Weight: 144.13

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Acids, bases, oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 20577-61-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl acetopyruvate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 20577-61-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 20577-61-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 20577-61-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：结晶（苯），熔点为 63-64℃。

用途：作为磺胺甲基异噁唑的中间体。

生产方法：可通过草酸二甲酯与丙酮缩合制备得到。

反应信息

• 作为反应物：
  描述：

  乙酰丙酮酸甲酯 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以25%的产率得到乙酰丙酮酸
  参考文献：
  名称：

  新型水溶性铂配合物（1R，2R-环己二胺-N，N'）[2-羟基-4-氧代-2-戊烯基（2-）-O2]铂（II）的合成，结构和抗肿瘤活性。

  摘要：

  二氢（1R，2R-环己二胺）铂（II）与2,4-二氧戊酸反应生成水溶性络合物，（1R，2R-环己二胺-N，N'）[2-羟基-4-氧- 2-戊烯基（2-）-O2]铂（II）。配合物的结构通过X射线晶体分析确定。数据表明2，4-二氧代戊酸的乙酰丙酮基部分与铂（II）的螯合。该复合物在小鼠中显示出对小鼠白血病L1210的中等抗肿瘤活性（在200 mg / kg的剂量下T / C = 195％）和对顺铂耐药L1210白血病的高活性（在25 mg剂量下T / C = 275％） /公斤）。

  DOI：

  10.1248/cpb.41.357
• 作为产物：
  描述：

  草酸二甲酯 、 丙酮 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以68%的产率得到乙酰丙酮酸甲酯
  参考文献：
  名称：

  新型水溶性铂配合物（1R，2R-环己二胺-N，N'）[2-羟基-4-氧代-2-戊烯基（2-）-O2]铂（II）的合成，结构和抗肿瘤活性。

  摘要：

  二氢（1R，2R-环己二胺）铂（II）与2,4-二氧戊酸反应生成水溶性络合物，（1R，2R-环己二胺-N，N'）[2-羟基-4-氧- 2-戊烯基（2-）-O2]铂（II）。配合物的结构通过X射线晶体分析确定。数据表明2，4-二氧代戊酸的乙酰丙酮基部分与铂（II）的螯合。该复合物在小鼠中显示出对小鼠白血病L1210的中等抗肿瘤活性（在200 mg / kg的剂量下T / C = 195％）和对顺铂耐药L1210白血病的高活性（在25 mg剂量下T / C = 275％） /公斤）。

  DOI：

  10.1248/cpb.41.357

文献信息

• [EN] SUBSTITUTED PYRAZOLE AND PYRROLE COMPOUNDS AND METHODS FOR USING THEM FOR INHIBITION OF INITIATION OF TRANSLATION AND TREATMENT OF DISEASES AND DISORDERS RELATING THERETO<br/>[FR] COMPOSÉS PYRAZOLE ET PYRROLE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CES DERNIERS POUR L'INHIBITION DE L'INITIATION DE LA TRADUCTION ET LE TRAITEMENT DE MALADIES ET DE TROUBLES ASSOCIÉS À CETTE DERNIÈRE
  申请人：BANTAM PHARMACEUTICAL LLC

  公开号：WO2016196644A1

  公开（公告）日：2016-12-08

  Disclosed are pyrazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure (I) and pharmaceutically acceptable salts and /V-oxides thereof, wherein X1, X2, Z1, Z2, the ring system denoted by "a", R1, A1A, L1B, A1B, L1A, L2, Q, L3, R3, A4A, L4B, A4B, L4A, R4, L5, and R5 are as described herein. In certain embodiments, compounds disclosed herein disrupt the elF4E/eiF4G interaction, and can be used to treat hyperproliferative disorder, a neurological disease or disorder, or autism.

  揭示了吡唑化合物，以及其药物组合物和使用方法。其中一种实施例是具有结构（I）及其药用可接受的盐和/或氧化物，其中X1、X2、Z1、Z2、由“a”表示的环系统、R1、A1A、L1B、A1B、L1A、L2、Q、L3、R3、A4A、L4B、A4B、L4A、R4、L5和R5如本文所述。在某些实施例中，本文所披露的化合物破坏elF4E/eiF4G相互作用，并可用于治疗过度增殖性疾病、神经系统疾病或障碍，或自闭症。
• [EN] COMPOUNDS AND THERAPEUTIC USES THEREOF<br/>[FR] COMPOSÉS ET SES UTILISATIONS THÉRAPEUTIQUES
  申请人：MYREXIS INC

  公开号：WO2012177782A1

  公开（公告）日：2012-12-27

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and complications associated with these diseases and disorders.

  这项发明涉及化合物、药物组合物和方法，用于治疗癌症、全身性或慢性炎症、类风湿性关节炎、糖尿病、肥胖症、T细胞介导的自身免疫疾病、缺血以及与这些疾病和疾病相关并发症。
• Design, Synthesis, and Structure–Activity Relationship of a Novel Series of GluN2C-Selective Potentiators
  作者：Sommer S. Zimmerman、Alpa Khatri、Ethel C. Garnier-Amblard、Praseeda Mullasseril、Natalie L. Kurtkaya、Stefka Gyoneva、Kasper B. Hansen、Stephen F. Traynelis、Dennis C. Liotta

  DOI：10.1021/jm401695d

  日期：2014.3.27

  herein describe a novel series of pyrrolidinones that selectively potentiate only NMDA receptors that contain the GluN2C subunit. The most active analogues tested were over 100-fold selective for recombinant GluN2C-containing receptors over GluN2A/B/D-containing NMDA receptors as well as AMPA and kainate receptors. This series represents the first class of allosteric potentiators that are selective

  NMDA受体是介导慢速的Ca GluN1和GluN2A-d亚基组成的四聚体复合2+ -兴奋性突触传递的渗透组分。NMDA 受体与广泛的神经系统疾病有关，因此代表了一个重要的治疗靶点。我们在此描述了一系列新型吡咯烷酮，它们选择性地仅增强含有 GluN2C 亚基的 NMDA 受体。测试的最活跃的类似物对重组 GluN2C 受体的选择性是对 GluN2A/B/D 含 NMDA 受体以及 AMPA 和红藻氨酸受体的 100 倍以上。该系列代表了第一类对含二异聚体 GluN2C 的 NMDA 受体具有选择性的变构增效剂。
• Synthesis, Acaricidal Activity, and Structure–Activity Relationships of Pyrazolyl Acrylonitrile Derivatives
  作者：Haibo Yu、Yan Cheng、Man Xu、Yuquan Song、Yanmei Luo、Bin Li

  DOI：10.1021/acs.jafc.6b04221

  日期：2016.12.28

  novel pyrazolyl acrylonitrile derivatives was designed, targeting Tetranychus cinnabarinus, and synthesized. Their structures were identified by combination of 1H NMR, 13C NMR, and MS spectra. The structures of compounds 18 and 19 were further confirmed by X-ray diffraction. Extensive greenhouse bioassays indicated that compound 19 exhibits excellent acaricidal activity against all developmental stages

  设计并合成了一系列新颖的吡唑基丙烯腈衍生物，并以朱砂叶螨（Tetranychus cinnabarinus）为靶标。它们的结构通过1 H NMR，13 C NMR和MS光谱的组合来鉴定。化合物18和19的结构通过X射线衍射进一步证实。大量的温室生物测定表明，化合物19对朱砂毛虫的所有发育阶段均表现出优异的杀螨活性，优于商品化的嘧菌草醚和螺二氯芬。结果表明，化合物19的急性毒性对哺乳动物来说是相当低的。还讨论了结构与活动之间的关系。
• [EN] PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS PHÉNYLALANINES ET LEUR UTILISATION COMME MODULATEURS NON PEPTIDIQUES DU RÉCEPTEUR DE GLP-1
  申请人：ARGUSINA INC

  公开号：WO2011094890A1

  公开（公告）日：2011-08-11

  Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula (I), pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metabolic disorder.

  本文提供了非肽类GLP-1受体调节剂化合物，例如，Formula (I)的化合物，包括这些化合物的药物组合物，以及其制备方法。还提供了这些化合物用于治疗代谢紊乱的方法。

表征谱图